Mr. Cramer runs his own consulting business, has over 30 years’ experience and is a proven and focused medical device & diagnostics CEO. He has significant experience driving change by instilling a culture of high performance and implementing growth strategies as well as operational improvement initiatives, resulting in a track-record of successful exits.
Scott joined Accriva Diagnostics in December 2013 as the President & CEO. The Company had a portfolio of diagnostics devices for coagulation and platelet function testing. The Company closed all NJ operations and moved to a new facility in San Diego. Accriva was successfully sold to Werfen Life in January 2017 for $380M.
Prior to Accriva, Scott worked as an EIR with Warburg Pincus in 2013. From March 2010 to Dec. 2012 Scott was President and CEO of Novasys Medical. The Company was focused on treating women with stress incontinence. Novasys was sold to Roper Industries in Dec. 2012.
Prior to joining Novasys, he served as President and CEO of Bacchus Vascular, a company focused on peripheral vascular disease, where he successfully negotiated the sale of the Company to Covidien plc in March 2009.
Previously, Scott was the Senior Vice President of U.S. Sales and Services for VNUS Medical, which was also acquired by Covidien plc. Scott joined VNUS in 2000.
From 1997 through 2000, Scott was Vice President Sales at EndoSonics, a cardiovascular device company which later became Volcano Corporation. From 1996 to 1997, he served as NSM at Cardiometrics, Inc., which was acquired by Endosonics Corporation. From 1990 to 1995, Scott held several positions at Baxter Healthcare Corporation’s cardiovascular division.
Scott currently serves on the Board of Directors of Veran Medical®, and is Chairman of Biocoat Incorporated. Scott served as Executive Chairman of NeuWave Medical (Sold to J&J April 2016, $300M), and has also previously served on the Board of Directors of Accriva, Vascular Insights, AccuVein, Venous Health, Novasys and Bacchus. He serves on the Investment Advisory Committee for Venture Investors. He holds a B.S. degree in Finance from Philadelphia University.